Market
Story
Merck's HPV Vaccine for Men Approved by China’s Drug Regulator for Ages 9-26, First of Its Kind
Jan 8, 2025, 04:50 AM
China's drug regulator has approved Merck's human papillomavirus (HPV) vaccine for men, marking a significant expansion for the U.S. pharmaceutical company in an emerging market. The vaccine is specifically authorized for males aged 9 to 26 and is the first of its kind in China. This approval comes after a decline in demand among women for the vaccine, which had previously surged. Merck's announcement, made via its Chinese subsidiary, MSD, highlights the potential for growth in a new demographic following the approval by China's medical products administration.
View original story
Similar markets
Less than $500 million • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
$500 million to $1 billion • 25%
No • 50%
Yes • 50%
European Union • 25%
United States • 25%
Other • 25%
China • 25%
Moderna • 25%
Pfizer • 25%
Other • 25%
GlaxoSmithKline • 25%
More than 10 countries • 25%
6 to 10 countries • 25%
1 to 5 countries • 25%
No countries • 25%
More than 3 million • 25%
2-3 million • 25%
1-2 million • 25%
Less than 1 million • 25%
